<?xml version='1.0' encoding='utf-8'?>
<document id="7102525"><sentence text="Pharmacokinetics of pindolol in humans and several animal species."><entity charOffset="20-28" id="DDI-PubMed.7102525.s1.e0" text="pindolol" /></sentence><sentence text="The absorption, distribution, detoxification, and excretion of pindolol were investigated in mice, rats, dogs, rhesus monkeys, and humans" /><sentence text=" The absorption was very good in all species; however, the quantitative composition of the final excretion products was unique for each species" /><sentence text=" Considerable interspecies variation was also apparent with respect to excretion patterns" /><sentence text=" The pharmacokinetics of pindolol in humans was investigated in single- and multiple-dose studies"><entity charOffset="25-33" id="DDI-PubMed.7102525.s5.e0" text="pindolol" /></sentence><sentence text=" All results were in agreement with a three-compartment model" /><sentence text=" The absorption was rapid and a first-pass effect of 12% to 25% of the dose (mean 20%) was calculated" /><sentence text=" The half-lives of the excretion of radioactivity were 3" /><sentence text="0, 1" /><sentence text="2, and less than 100 hours" /><sentence text=" The pharmacokinetic parameters obtained in normal volunteers were compared with corresponding values obtained in patients with hypertension, renal insufficiency, or liver impairment" /><sentence text=" Results in these patients were not significantly different" /><sentence text=" The bioavailability interaction was investigated with drugs often coadministered with a beta blocker" /><sentence text=" No drug-drug interaction was found with hydralazine, hydrochlorothiazide, coumarin, or aspirin"><entity charOffset="41-52" id="DDI-PubMed.7102525.s14.e0" text="hydralazine" /><entity charOffset="54-73" id="DDI-PubMed.7102525.s14.e1" text="hydrochlorothiazide" /><entity charOffset="75-83" id="DDI-PubMed.7102525.s14.e2" text="coumarin" /><entity charOffset="88-95" id="DDI-PubMed.7102525.s14.e3" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.7102525.s14.e0" e2="DDI-PubMed.7102525.s14.e0" /><pair ddi="false" e1="DDI-PubMed.7102525.s14.e0" e2="DDI-PubMed.7102525.s14.e1" /><pair ddi="false" e1="DDI-PubMed.7102525.s14.e0" e2="DDI-PubMed.7102525.s14.e2" /><pair ddi="false" e1="DDI-PubMed.7102525.s14.e0" e2="DDI-PubMed.7102525.s14.e3" /><pair ddi="false" e1="DDI-PubMed.7102525.s14.e1" e2="DDI-PubMed.7102525.s14.e1" /><pair ddi="false" e1="DDI-PubMed.7102525.s14.e1" e2="DDI-PubMed.7102525.s14.e2" /><pair ddi="false" e1="DDI-PubMed.7102525.s14.e1" e2="DDI-PubMed.7102525.s14.e3" /><pair ddi="false" e1="DDI-PubMed.7102525.s14.e2" e2="DDI-PubMed.7102525.s14.e2" /><pair ddi="false" e1="DDI-PubMed.7102525.s14.e2" e2="DDI-PubMed.7102525.s14.e3" /></sentence><sentence text=" Pindolol coadministration resulted in a possible lowering of digoxin levels"><entity charOffset="62-69" id="DDI-PubMed.7102525.s15.e0" text="digoxin" /></sentence><sentence text=" The bioavailability of the tablet dosage forM proposed for marketing was compared to that of a solution and found to be optimal" /><sentence text="" /></document>